90673-37-3

Basic information

• Product Name: 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI)
• Synonyms: 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI);Hexahydro-7-Methyl-5H-1,4-Diazepin-5-one;Hexahydro-7-Methyl-5H-1,4...;7-Methyl-1,4-diazepan-5-one
• CAS NO: 90673-37-3
• Molecular Formula: C₆H₁₂N₂O
• Molecular Weight: 128.17228
• Product Categories: PIPERAZINE
• Mol File: 90673-37-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI)(90673-37-3)
• EPA Substance Registry System: 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI)(90673-37-3)

Safety Data

• Hazardous Substances Data: 90673-37-3(Hazardous Substances Data)

Usage

General Description

The chemical "5H-1,4-Diazepin-5-one, hexahydro-7-methyl-(7CI)" is a heterocyclic compound with a seven membered ring containing four carbon atoms, two nitrogen atoms, and one oxygen atom. It is classified as a diazepinone and is also known as 7-methyl-1,4-diazepin-5(4H)-one. 5H-1,4-Diazepin-5-one,hexahydro-7-methyl-(7CI) is used in the synthesis of pharmaceuticals and can also be found as a component in some research chemicals. It has potential applications in the pharmaceutical industry due to its chemical structure and reactivity in organic synthesis. Additionally, it may have biological activity that makes it interesting for further research and development.

Upstream product

• 107-15-3 ethylenediamine 
• 623-70-1 ethyl (E)-crotonate 
• 1240195-07-6 (Z)-methyl 3-((2-((tert.-butoxycarbonyl)amino)ethyl)amino)but-2-enoate 
• 89600-61-3 7-methyl-3,4-dihydro-1H-1,4-diazepin-5(2H)-one 

Downstream Products

• 935843-58-6 7-methyl-5-oxo-[1,4]diazepane-1-carboxylic acid tert-butyl ester 
• 1638743-92-6 1-tert-butoxycarbonyl-7-methyl-1,4-diazacycloheptane 
• 1394957-73-3 (7R)-7-methyl-1,4-diazepan-5-one 
• 1394957-78-8 (7S)-1-(3-mesitylpropanoyl)-7-methyl-1,4-diazepan-5-one 
• 1643770-78-8 (7S)-1-((2S)-2-methoxy-2-phenylacetyl)-7-methyl-1,4-diazepan-5-one 
• 1643770-82-4 (7R)-1-((2S)-2-methoxy-2-phenylacetyl)-7-methyl-1,4-diazepan-5-one 
• 1001401-59-7 (7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone 
• 1352834-55-9 (4-(5-chlorobenzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone 
• 1030377-33-3 Suvorexant 

Relevant articles and documents

NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT

The present invention relates to a process for the preparation of a compound of formula (A), Further, the present invention relates to the respective compound (A) as such and to its use in the preparation of antifungal agent.

QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES

The present invention relates to a quinazolinone or isoquinolinone derivative of formula I, wherein R1 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-3alkyl, C2-6alkenyl, C2-6alkynyl, said C1-6alkyl, C3-6cycloalkyl and C3-6cycloalkylC1-3alkyl being optionally substituted with hydroxy, C1-6alkyloxy, cyano or one or more halogens; R2 is C6-10aryl optionally substituted with one to three substituents selected from halogen, hydroxy, cyano, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy and C3-6cycloalkyloxy, said C1-6alkyl, C3-6 cycloalkyl, C1-6 alkyloxy and C3-6Cycloalkyloxy being optionally substituted with one or more halogens; or R2 is a 5-10 membered heteroaryl ring system comprising a heteroatom selected from N, O and S and optionally substituted with a substituent selected from methyl, C1-6alkyloxy and halogen; or R2 is C4-7cycloalkyl; R3 is an optional substituent selected from C1-6alkyl, C1-6alkyloxy and halogen, said C1-6alkyl and C1-6alkyloxy being optionally substituted with one or more halogens; R4 is a group located at the 6- or 7- position of the quinazolinone or isoquinolinone ring having the formula Il, wherein R5 together with one of R6 forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR9, said heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo or R5 together with one of R7 and R8 forms a 6-8 membered heterocyclic ring optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; Each R6 is independently H, halogen or C1-4alkyl optionally substituted with halogen or SO2CH3 or one of R6 together with R5 forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR9, said heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; R7 and R8 are independently H, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylc1-3alkyl, cyanoC1-3alkyl, C6-10aryl, C6-10arylC1-3alkyl, C1-3alkyloxyC1-3alkyl or C1-6acyl said C1-6alkyl, C3-6cycloalkyl and C3-6cycloalkylC1-3alkyl being optionally substituted with hydroxy, 1 or more halogens or diC1-2alkylamino; or R7 and R8 together with the nitrogen to which they are bonded form a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR10, said heterocyclic ring being optionally substituted with one or two substituents selected from C1-6alkyl, halogen, hydroxy,